United Therapeutics Company Profile (NASDAQ:UTHR)

About United Therapeutics (NASDAQ:UTHR)

United Therapeutics logoUnited Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:UTHR
  • CUSIP: 91307C10
  • Web: www.unither.com
Capitalization:
  • Market Cap: $5.52 billion
  • Outstanding Shares: 45,056,000
Average Prices:
  • 50 Day Moving Avg: $122.63
  • 200 Day Moving Avg: $138.59
  • 52 Week Range: $97.52 - $169.89
P/E:
  • Trailing P/E Ratio: 8.61
  • Foreward P/E Ratio: 11.11
  • P/E Growth: -0.32
Sales & Book Value:
  • Annual Revenue: $1.6 billion
  • Price / Sales: 3.45
  • Book Value: $45.84 per share
  • Price / Book: 2.67
Profitability:
  • EBIDTA: $993.4 million
  • Net Margins: 44.40%
  • Return on Equity: 41.78%
  • Return on Assets: 32.80%
Debt:
  • Current Ratio: 4.41%
  • Quick Ratio: 4.11%
Misc:
  • Average Volume: 650,349 shs.
  • Beta: 1.42
  • Short Ratio: 9.65
 

Frequently Asked Questions for United Therapeutics (NASDAQ:UTHR)

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings results on Wednesday, April, 26th. The company reported $3.89 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $3.13 by $0.77. The company had revenue of $370.50 million for the quarter, compared to the consensus estimate of $399.59 million. United Therapeutics had a net margin of 44.40% and a return on equity of 41.78%. The company's revenue for the quarter was up .4% on a year-over-year basis. During the same period last year, the firm posted $3.02 EPS. View United Therapeutics' Earnings History.

When will United Therapeutics make its next earnings announcement?

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for United Therapeutics.

Where is United Therapeutics' stock going? Where will United Therapeutics' stock price be in 2017?

12 brokerages have issued 12 month target prices for United Therapeutics' stock. Their predictions range from $95.00 to $213.00. On average, they anticipate United Therapeutics' share price to reach $132.82 in the next twelve months. View Analyst Ratings for United Therapeutics.

What are analysts saying about United Therapeutics stock?

Here are some recent quotes from research analysts about United Therapeutics stock:

  • 1. Cowen and Company analysts commented, "1Q Revenues were weak across the prostacyclin PAH franchise." (4/26/2017)
  • 2. Credit Suisse Group AG analysts commented, "The recent acquisition of UTHR's competitor has driven a large M&A premium in UTHR shares, and we see downside due to potential near-term and generic risk starting late 2017-2018. United Therapeutics' product franchise consists of pulmonary arterial hypertension (PAH) therapies. PAH is essentially high blood pressure in the lungs. We think an acquisition for United Therapeutics is unlikely in the near term since the company has mentioned doing deals to acquire. We see catalysts in the coming month that could lead to downside in shares, especially with shares trading above (~20%), the level at which we see the fundamental value of the company. In the long term, we remain more cautious on what the current valuation would suggest around risk to UTHR's PAH franchise from generics launching as early as 2018. We think that the stock trades at a higher non-GAAP P/E multiple than what consensus actually shows; we estimate 2018 and 2019 P/E multiples of 15x and 20x vs. consensus of 10x and 11x, respectively." (3/16/2017)
  • 3. Jefferies Group LLC analysts commented, "Our physician poll indicates continuing competitor Uptravi impact on UTHR's treprostinil franchise & meaningful headwinds from generic Remodulin - potentially ~35% of current sales at risk. Yet, current consensus est's do not reflect such downside risks, particularly a potential real threat from generic Remodulin in 2018. Downgrading UTHR to Underperform from Hold, but keeping $116 PT." (3/6/2017)
  • 4. Wedbush analysts commented, "With consistent YoY growth in revenues, free cash flow and a deep pipeline of diverse assets in late-stage development, we continue to believe UTHR continues to be an attractive long-term investment. ' Q4 and 2016 top and bottom line missed on seasonal choppiness and transient warehousing of Remodulin and Tyvaso patients. Reported Q4/FY:16 revenues of $409MM/$1599MM came in below consensus estimates of $416MM/$1605MM. GAAP EPS of $2.43/$15.25 also missed consensus estimates of $3.68/$16.46. While Remodulin and Adcirca beat, Tyvaso and Orenitram missed. Management indicated their view that patient warehousing with oral PAH medications is transient and anticipates sales acceleration for Tyvaso and Remodulin later in 2017 as the effect of oral PAH medications begins to wane and PAH patients need a new medication. UTHR ended 2016 with ~$1.053BN in cash & cash eq. Management implied that instead of pursing another share buyback, they may announce business development activities." (2/27/2017)
  • 5. According to Zacks Investment Research, "United Therapeutics’ fourth-quarter results were disappointing, with both earnings and sales missing estimates. At the call, the company said that growth of its PAH drugs Orenitram, Tyvaso and Remodulin were slower than expected due to competition from Uptravi. Competition in the PAH market is on the rise. Meanwhile, we believe the company needs to use cash suitably to deal with generic competition for its flagship product Remodulin that could materialize post Oct 2017 and work on expanding its portfolio. The company is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Though Orenitram sales growth was slow in 2016, management estimates the drug to have $1 billion peak revenue potential. United Therapeutics’ shares outperformed the drugs industry in the past one year." (2/27/2017)

Are investors shorting United Therapeutics?

United Therapeutics saw a drop in short interest in April. As of April 28th, there was short interest totalling 6,265,267 shares, a drop of 0.1% from the April 13th total of 6,273,744 shares. Based on an average trading volume of 815,421 shares, the days-to-cover ratio is presently 7.7 days.

Who are some of United Therapeutics' key competitors?

Who owns United Therapeutics stock?

United Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.52%), FMR LLC (9.19%), Vanguard Group Inc. (8.40%), State Street Corp (4.43%), Palo Alto Investors LLC (4.18%) and AQR Capital Management LLC (3.85%). Company insiders that own United Therapeutics stock include Christopher Patusky, Louis W Sullivan, Martine A Rothblatt, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

Who sold United Therapeutics stock? Who is selling United Therapeutics stock?

United Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, UBS Asset Management Americas Inc., NN Investment Partners Holdings N.V., First Trust Advisors LP, Russell Investments Group Ltd., Acadian Asset Management LLC, Lazard Asset Management LLC and Tekla Capital Management LLC. Company insiders that have sold United Therapeutics stock in the last year include Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics.

Who bought United Therapeutics stock? Who is buying United Therapeutics stock?

United Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., AQR Capital Management LLC, Vanguard Group Inc., BNP Paribas Arbitrage SA, Old Mutual Global Investors UK Ltd., Morgan Stanley, Cornerstone Capital Management Holdings LLC. and State Street Corp. View Insider Buying and Selling for United Therapeutics.

How do I buy United Therapeutics stock?

Shares of United Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of United Therapeutics stock cost?

One share of United Therapeutics stock can currently be purchased for approximately $122.57.

Analyst Ratings

Consensus Ratings for United Therapeutics (NASDAQ:UTHR) (?)
Ratings Breakdown: 3 Sell Ratings, 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 1.92)
Consensus Price Target: $132.82 (8.36% upside)

Analysts' Ratings History for United Therapeutics (NASDAQ:UTHR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/28/2017Jefferies Group LLCReiterated RatingUnderperform$116.00 -> $105.00LowView Rating Details
4/27/2017WedbushReiterated RatingOutperform -> Outperform$229.00 -> $213.00LowView Rating Details
4/26/2017Cowen and CompanyReiterated RatingHold$121.00LowView Rating Details
4/17/2017HC WainwrightReiterated RatingHold$95.00LowView Rating Details
4/11/2017JPMorgan Chase & Co.Set Price TargetHold$125.00LowView Rating Details
4/3/2017Oppenheimer Holdings Inc.Reiterated RatingBuyMediumView Rating Details
4/3/2017Credit Suisse Group AGReiterated RatingUnderperform$120.00HighView Rating Details
2/23/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> Neutral$145.00N/AView Rating Details
2/23/2017Leerink SwannBoost Price TargetMarket Perform$127.00 -> $148.00N/AView Rating Details
1/19/2017Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
11/29/2016Barclays PLCDowngradeEqual Weight -> Underweight$115.00 -> $100.00N/AView Rating Details
8/23/2016ArgusReiterated RatingHoldN/AView Rating Details
4/11/2016Royal Bank of CanadaReiterated RatingSector Perform$150.00 -> $122.00N/AView Rating Details
7/20/2015Goldman Sachs Group IncLower Price TargetSell$98.00 -> $95.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for United Therapeutics (NASDAQ:UTHR)
Earnings by Quarter for United Therapeutics (NASDAQ:UTHR)
Earnings History by Quarter for United Therapeutics (NASDAQ:UTHR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017        
4/26/2017Q1 2017$3.13$3.89$399.59 million$370.50 millionViewN/AView Earnings Details
2/22/2017Q416$3.61$4.12$415.51 million$409.00 millionViewListenView Earnings Details
10/27/2016Q316$3.38$4.36$400.58 million$408.20 millionViewListenView Earnings Details
7/28/2016Q216$3.22$4.55$395.15 million$412.60 millionViewListenView Earnings Details
4/28/2016Q116$3.21$3.02$395.02 million$369.00 millionViewListenView Earnings Details
2/25/2016Q415$2.70$3.68$388.29 million$404.90 millionViewListenView Earnings Details
10/27/2015Q315$2.35$3.55$363.51 million$386.20 millionViewListenView Earnings Details
7/28/2015Q215$2.31$2.55$360.41 million$347.20 millionViewListenView Earnings Details
4/28/2015Q115$2.14$2.55$353.50 million$327.60 millionViewN/AView Earnings Details
2/24/2015Q414$2.03$3.21$336.22 million$346.40 millionViewN/AView Earnings Details
10/28/2014Q314$1.97$3.91$335.10 million$330.00 millionViewN/AView Earnings Details
7/29/2014Q214$1.75$2.57$308.04 million$322.80 millionViewN/AView Earnings Details
4/29/2014Q114$1.65$1.77$300.14 million$289.40 millionViewN/AView Earnings Details
2/25/2014Q413$1.51$2.88$295.43 million$289.02 millionViewN/AView Earnings Details
10/29/2013Q313$1.59$2.98$279.02 million$302.20 millionViewN/AView Earnings Details
7/25/2013Q2 2013$1.47$1.52$250.17 million$280.60 millionViewN/AView Earnings Details
4/25/2013Q1 2013$1.47$1.19$241.14 million$245.14 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.25$1.65$233.41 million$243.82 millionViewN/AView Earnings Details
11/1/2012Q312$1.26$2.82$227.63 million$242.50 millionViewN/AView Earnings Details
7/26/2012$1.23$1.34ViewN/AView Earnings Details
4/26/2012$1.00$1.32ViewN/AView Earnings Details
2/14/2012$0.85$0.77ViewN/AView Earnings Details
10/27/2011$0.88$1.32ViewN/AView Earnings Details
7/28/2011$0.49$1.27ViewN/AView Earnings Details
4/28/2011$0.64$1.29ViewN/AView Earnings Details
2/15/2011$0.62$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for United Therapeutics (NASDAQ:UTHR)
2017 EPS Consensus Estimate: $14.38
2018 EPS Consensus Estimate: $13.41
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$3.08$3.89$3.37
Q2 20174$3.43$4.47$3.81
Q3 20174$3.48$3.93$3.77
Q4 20174$3.08$3.81$3.43
Q1 20181$3.56$3.56$3.56
Q2 20181$3.30$3.30$3.30
Q3 20181$3.36$3.36$3.36
Q4 20181$3.19$3.19$3.19
(Data provided by Zacks Investment Research)

Dividends

Dividend History for United Therapeutics (NASDAQ:UTHR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for United Therapeutics (NASDAQ:UTHR)
Insider Ownership Percentage: 7.50%
Insider Trades by Quarter for United Therapeutics (NASDAQ:UTHR)
Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)
Insider Trades by Quarter for United Therapeutics (NASDAQ:UTHR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Martine A RothblattCEOSell1,261$120.72$152,227.92View SEC Filing  
5/11/2017Martine A RothblattCEOSell1,259$122.00$153,598.00View SEC Filing  
5/4/2017Martine A RothblattCEOSell1,258$122.24$153,777.92View SEC Filing  
4/27/2017Martine A RothblattCEOSell1,262$120.78$152,424.36View SEC Filing  
4/20/2017Martine A RothblattCEOSell1,260$121.14$152,636.40View SEC Filing  
4/13/2017Martine A RothblattCEOSell1,258$122.12$153,626.96View SEC Filing  
4/6/2017Martine A RothblattCEOSell1,257$122.39$153,844.23View SEC Filing  
3/30/2017Martine A RothblattCEOSell1,230$134.56$165,508.80View SEC Filing  
3/23/2017Martine A RothblattCEOSell1,219$139.33$169,843.27View SEC Filing  
3/22/2017Tommy G ThompsonDirectorSell2,000$139.37$278,740.00View SEC Filing  
3/16/2017Martine A RothblattCEOSell1,218$140.16$170,714.88View SEC Filing  
3/9/2017Martine A RothblattCEOSell1,206$146.72$176,944.32View SEC Filing  
3/2/2017Martine A RothblattCEOSell1,203$148.49$178,633.47View SEC Filing  
2/23/2017Martine A RothblattCEOSell1,208$145.16$175,353.28View SEC Filing  
2/16/2017Martine A RothblattCEOSell1,173$167.92$196,970.16View SEC Filing  
1/12/2017Christopher PatuskyDirectorSell5,000$141.99$709,950.00View SEC Filing  
1/12/2017Martine A RothblattCEOSell1,214$142.37$172,837.18View SEC Filing  
1/5/2017Martine A RothblattCEOSell1,208$145.73$176,041.84View SEC Filing  
12/29/2016Martine A RothblattCEOSell1,211$143.63$173,935.93View SEC Filing  
12/22/2016Martine A RothblattCEOSell1,218$140.23$170,800.14View SEC Filing  
12/15/2016Martine A RothblattCEOSell1,212$143.11$173,449.32View SEC Filing  
12/8/2016Martine A RothblattCEOSell1,236$131.78$162,880.08View SEC Filing  
12/6/2016Richard GiltnerDirectorSell5,000$133.37$666,850.00View SEC Filing  
12/1/2016Martine A RothblattCEOSell1,246$126.86$158,067.56View SEC Filing  
11/25/2016Martine A RothblattCEOSell1,233$132.81$163,754.73View SEC Filing  
11/17/2016Martine A RothblattCEOSell1,232$132.94$163,782.08View SEC Filing  
11/10/2016Christopher PatuskyDirectorSell5,000$131.42$657,100.00View SEC Filing  
11/10/2016Martine A RothblattCEOSell1,240$129.82$160,976.80View SEC Filing  
11/3/2016Martine A RothblattCEOSell1,272$116.94$148,747.68View SEC Filing  
10/27/2016Martine A RothblattCEOSell1,272$117.06$148,900.32View SEC Filing  
10/20/2016Martine A RothblattCEOSell1,282$113.30$145,250.60View SEC Filing  
10/13/2016Martine A RothblattCEOSell1,269$117.99$149,729.31View SEC Filing  
10/6/2016Martine A RothblattCEOSell1,260$121.17$152,674.20View SEC Filing  
9/29/2016Martine A RothblattCEOSell1,272$116.94$148,747.68View SEC Filing  
9/26/2016Tommy G ThompsonDirectorSell1,291$125.57$162,110.87View SEC Filing  
9/22/2016Martine A RothblattCEOSell1,249$125.87$157,211.63View SEC Filing  
9/15/2016Martine A RothblattCEOSell1,258$122.34$153,903.72View SEC Filing  
9/8/2016Martine A RothblattCEOSell1,254$123.44$154,793.76View SEC Filing  
9/1/2016Christopher PatuskyDirectorSell5,000$122.73$613,650.00View SEC Filing  
9/1/2016Martine A RothblattCEOSell1,257$122.81$154,372.17View SEC Filing  
8/25/2016Martine A RothblattCEOSell1,250$125.29$156,612.50View SEC Filing  
8/18/2016Martine A RothblattCEOSell1,249$125.88$157,224.12View SEC Filing  
8/11/2016Martine A RothblattCEOSell1,253$124.09$155,484.77View SEC Filing  
8/4/2016Martine A RothblattCEOSell1,249$125.78$157,099.22View SEC Filing  
7/28/2016Martine A RothblattCEOSell1,271$117.05$148,770.55View SEC Filing  
7/21/2016Martine A RothblattCEOSell1,284$112.77$144,796.68View SEC Filing  
7/14/2016Martine A RothblattCEOSell1,292$110.05$142,184.60View SEC Filing  
7/7/2016Martine A RothblattCEOSell1,293$109.87$142,061.91View SEC Filing  
6/30/2016Martine A RothblattCEOSell1,308$105.10$137,470.80View SEC Filing  
6/23/2016Martine A RothblattCEOSell1,312$104.07$136,539.84View SEC Filing  
6/16/2016Martine A RothblattCEOSell1,308$105.18$137,575.44View SEC Filing  
6/9/2016Martine A RothblattCEOSell1,277$114.99$146,842.23View SEC Filing  
6/8/2016Tommy G ThompsonDirectorSell2,000$115.62$231,240.00View SEC Filing  
6/2/2016Martine A RothblattCEOSell1,261$120.79$152,316.19View SEC Filing  
6/2/2016Raymond DwekDirectorSell3,000$118.82$356,460.00View SEC Filing  
5/26/2016Martine A RothblattCEOSell5,547$117.57$652,160.79View SEC Filing  
5/19/2016Martine A RothblattCEOSell5,546$110.75$614,219.50View SEC Filing  
5/12/2016Martine A RothblattCEOSell5,547$109.02$604,733.94View SEC Filing  
5/12/2016Raymond DwekDirectorSell3,000$110.00$330,000.00View SEC Filing  
5/5/2016Martine A RothblattCEOSell5,546$107.79$597,803.34View SEC Filing  
4/28/2016Martine A RothblattCEOSell5,547$106.81$592,475.07View SEC Filing  
4/21/2016Martine A RothblattCEOSell5,546$115.74$641,894.04View SEC Filing  
4/14/2016Martine A RothblattCEOSell5,547$114.32$634,133.04View SEC Filing  
4/7/2016Martine A RothblattCEOSell5,546$113.31$628,417.26View SEC Filing  
3/24/2016Martine A RothblattCEOSell5,546$110.80$614,496.80View SEC Filing  
3/17/2016Martine A RothblattCEOSell5,547$118.22$655,766.34View SEC Filing  
3/10/2016Martine A RothblattCEOSell5,546$123.41$684,431.86View SEC Filing  
3/3/2016Martine A RothblattCEOSell5,547$126.78$703,248.66View SEC Filing  
2/25/2016Martine A RothblattCEOSell5,546$122.45$679,107.70View SEC Filing  
2/18/2016Martine A RothblattCEOSell5,547$128.26$711,458.22View SEC Filing  
2/11/2016Martine A. RothblattCEOSell5,546$120.47$668,126.62View SEC Filing  
2/4/2016Martine A. RothblattCEOSell5,547$122.13$677,455.11View SEC Filing  
2/4/2016Raymond DwekDirectorSell3,000$122.66$367,980.00View SEC Filing  
1/28/2016Martine A. RothblattCEOSell5,546$124.00$687,704.00View SEC Filing  
1/21/2016Martine A. RothblattCEOSell5,547$127.00$704,469.00View SEC Filing  
1/14/2016Martine A. RothblattCEOSell5,546$135.94$753,923.24View SEC Filing  
1/7/2016Martine A. RothblattCEOSell5,547$145.84$808,974.48View SEC Filing  
1/7/2016Raymond DwekDirectorSell3,000$143.75$431,250.00View SEC Filing  
12/24/2015Martine A. RothblattCEOSell5,546$159.58$885,030.68View SEC Filing  
12/17/2015Martine A. RothblattCEOSell5,546$158.49$878,985.54View SEC Filing  
12/10/2015Martine A. RothblattCEOSell5,546$154.49$856,801.54View SEC Filing  
12/3/2015Martine A. RothblattCEOSell5,546$154.49$856,801.54View SEC Filing  
12/3/2015Raymond DwekDirectorSell3,000$157.22$471,660.00View SEC Filing  
11/27/2015Martine A. RothblattCEOSell5,561$153.81$855,337.41View SEC Filing  
11/19/2015Martine A. RothblattCEOSell9,661$148.56$1,435,238.16View SEC Filing  
11/12/2015Martine A. RothblattCEOSell4,115$147.72$607,867.80View SEC Filing  
11/5/2015Martine A. RothblattCEOSell4,115$149.16$613,793.40View SEC Filing  
11/5/2015Raymond DwekDirectorSell3,000$149.63$448,890.00View SEC Filing  
11/3/2015Richard GiltnerDirectorSell7,500$153.22$1,149,150.00View SEC Filing  
10/29/2015Martine A. RothblattCEOSell9,662$141.89$1,370,941.18View SEC Filing  
10/28/2015Martine A. RothblattCEOSell2,211$136.58$301,978.38View SEC Filing  
10/26/2015Martine A. RothblattCEOSell2,592$127.13$329,520.96View SEC Filing  
10/22/2015Martine A. RothblattCEOSell9,662$122.40$1,182,628.80View SEC Filing  
10/21/2015Martine A. RothblattCEOSell2,211$123.63$273,345.93View SEC Filing  
10/19/2015Martine A. RothblattCEOSell2,592$126.71$328,432.32View SEC Filing  
10/15/2015Martine A. RothblattCEOSell9,662$126.22$1,219,537.64View SEC Filing  
10/14/2015Martine A. RothblattCEOSell2,211$123.53$273,124.83View SEC Filing  
10/12/2015Martine A. RothblattCEOSell2,592$123.51$320,137.92View SEC Filing  
10/8/2015Martine A. RothblattCEOSell9,662$122.48$1,183,401.76View SEC Filing  
10/7/2015Martine A. RothblattCEOSell2,211$120.88$267,265.68View SEC Filing  
10/5/2015Martine A. RothblattCEOSell2,592$126.88$328,872.96View SEC Filing  
10/1/2015Martine A. RothblattCEOSell6,326$131.11$829,401.86View SEC Filing  
10/1/2015Paul A. MahonEVPSell6,000$129.38$776,280.00View SEC Filing  
10/1/2015Raymond DwekDirectorSell3,000$131.32$393,960.00View SEC Filing  
9/29/2015Martine A. RothblattCEOSell2,592$134.25$347,976.00View SEC Filing  
9/29/2015Tommy G. ThompsonDirectorSell5,000$139.19$695,950.00View SEC Filing  
9/24/2015Martine A. RothblattCEOSell9,662$139.26$1,345,530.12View SEC Filing  
9/23/2015Martine A. RothblattCEOSell2,211$142.05$314,072.55View SEC Filing  
9/21/2015Martine A. RothblattCEOSell2,592$150.81$390,899.52View SEC Filing  
9/17/2015Martine A. RothblattCEOSell9,662$152.02$1,468,817.24View SEC Filing  
9/16/2015Martine A. RothblattCEOSell2,211$151.93$335,917.23View SEC Filing  
9/14/2015Martine A. RothblattCEOSell2,592$153.08$396,783.36View SEC Filing  
9/10/2015Martine A. RothblattCEOSell4,115$152.95$629,389.25View SEC Filing  
9/9/2015Martine A. RothblattCEOSell2,211$152.77$337,774.47View SEC Filing  
9/8/2015Martine A. RothblattCEOSell2,592$152.80$396,057.60View SEC Filing  
9/3/2015Martine A. RothblattCEOSell9,662$153.67$1,484,759.54View SEC Filing  
9/3/2015Raymond DwekDirectorSell3,000$155.54$466,620.00View SEC Filing  
9/2/2015Martine A. RothblattCEOSell2,211$151.12$334,126.32View SEC Filing  
8/31/2015Martine A. RothblattCEOSell2,592$153.50$397,872.00View SEC Filing  
8/27/2015Martine A. RothblattCEOSell9,662$160.37$1,549,494.94View SEC Filing  
8/26/2015Martine A. RothblattCEOSell2,211$155.47$343,744.17View SEC Filing  
8/24/2015Martine A. RothblattCEOSell2,592$155.36$402,693.12View SEC Filing  
8/20/2015Martine A. RothblattCEOSell9,662$166.58$1,609,495.96View SEC Filing  
8/19/2015Martine A. RothblattCEOSell2,211$167.13$369,524.43View SEC Filing  
8/17/2015Martine A RothblattCEOSell2,592$166.61$431,853.12View SEC Filing  
8/13/2015Martine A RothblattCEOSell9,662$165.05$1,594,713.10View SEC Filing  
7/27/2015Martine A RothblattCEOSell2,592$166.38$431,256.96View SEC Filing  
7/23/2015Martine A RothblattCEOSell4,115$176.38$725,803.70View SEC Filing  
7/22/2015Martine A RothblattCEOSell2,211$174.55$385,930.05View SEC Filing  
7/20/2015Martine A RothblattCEOSell2,592$177.92$461,168.64View SEC Filing  
7/16/2015Martine A RothblattCEOSell9,662$175.51$1,695,777.62View SEC Filing  
7/15/2015Martine A RothblattCEOSell2,211$176.77$390,838.47View SEC Filing  
7/13/2015Martine A RothblattCEOSell2,592$172.42$446,912.64View SEC Filing  
7/9/2015Martine A RothblattCEOSell9,662$168.04$1,623,602.48View SEC Filing  
7/8/2015Martine A RothblattCEOSell2,211$167.13$369,524.43View SEC Filing  
7/6/2015Martine A RothblattCEOSell2,592$170.66$442,350.72View SEC Filing  
7/2/2015Martine A RothblattCEOSell6,326$170.69$1,079,784.94View SEC Filing  
7/2/2015Raymond DwekDirectorSell3,000$171.59$514,770.00View SEC Filing  
6/29/2015Martine A RothblattCEOSell2,592$172.86$448,053.12View SEC Filing  
6/25/2015Martine A RothblattCEOSell9,662$176.91$1,709,304.42View SEC Filing  
6/24/2015Martine A RothblattCEOSell2,211$179.68$397,272.48View SEC Filing  
6/22/2015Martine A RothblattCEOSell2,592$188.64$488,954.88View SEC Filing  
6/18/2015Louis W SullivanDirectorSell15,000$185.60$2,784,000.00View SEC Filing  
6/18/2015Martine A RothblattCEOSell9,662$185.72$1,794,426.64View SEC Filing  
6/17/2015Martine A RothblattCEOSell2,211$185.25$409,587.75View SEC Filing  
6/15/2015Martine A RothblattCEOSell2,592$185.15$479,908.80View SEC Filing  
6/11/2015Martine A RothblattCEOSell9,662$183.76$1,775,489.12View SEC Filing  
6/10/2015Martine A RothblattCEOSell2,211$180.87$399,903.57View SEC Filing  
6/8/2015Martine A RothblattCEOSell2,592$181.34$470,033.28View SEC Filing  
6/4/2015Martine A RothblattCEOSell9,662$181.94$1,757,904.28View SEC Filing  
6/4/2015Raymond DwekDirectorSell3,000$181.36$544,080.00View SEC Filing  
6/3/2015Martine A RothblattCEOSell2,211$184.49$407,907.39View SEC Filing  
6/1/2015Martine A RothblattCEOSell2,592$182.66$473,454.72View SEC Filing  
5/28/2015Martine A RothblattCEOSell9,662$180.88$1,747,662.56View SEC Filing  
5/27/2015Martine A RothblattCEOSell2,211$184.39$407,686.29View SEC Filing  
5/26/2015Martine A RothblattCEOSell2,592$182.64$473,402.88View SEC Filing  
5/21/2015Martine A RothblattCEOSell9,662$182.44$1,762,735.28View SEC Filing  
5/21/2015Tommy G ThompsonDirectorSell1,500$182.04$273,060.00View SEC Filing  
5/20/2015Martine A RothblattCEOSell2,211$182.80$404,170.80View SEC Filing  
5/18/2015Martine A RothblattCEOSell2,592$177.79$460,831.68View SEC Filing  
5/14/2015Martine A RothblattCEOSell9,662$174.07$1,681,864.34View SEC Filing  
5/13/2015Martine A RothblattCEOSell2,211$175.41$387,831.51View SEC Filing  
5/11/2015Martine A RothblattCEOSell2,592$179.55$465,393.60View SEC Filing  
5/7/2015Christopher CauseyDirectorSell1,500$167.94$251,910.00View SEC Filing  
5/7/2015Martine A RothblattCEOSell9,662$169.86$1,641,187.32View SEC Filing  
5/6/2015Martine A RothblattCEOSell2,211$169.22$374,145.42View SEC Filing  
5/4/2015Martine A RothblattCEOSell2,592$169.81$440,147.52View SEC Filing  
5/1/2015Raymond DwekDirectorSell3,000$159.58$478,740.00View SEC Filing  
4/30/2015Martine A RothblattCEOSell9,662$162.36$1,568,722.32View SEC Filing  
4/29/2015Martine A RothblattCEOSell2,211$164.29$363,245.19View SEC Filing  
4/28/2015Roger JeffsCEOSell5,000$163.31$816,550.00View SEC Filing  
4/27/2015Martine A RothblattCEOSell2,592$177.62$460,391.04View SEC Filing  
4/23/2015Martine A RothblattCEOSell9,662$187.35$1,810,175.70View SEC Filing  
4/22/2015Martine A RothblattCEOSell2,211$187.49$414,540.39View SEC Filing  
4/21/2015Roger JeffsCEOSell10,000$187.86$1,878,600.00View SEC Filing  
4/20/2015Martine A RothblattCEOSell2,592$184.86$479,157.12View SEC Filing  
4/16/2015Martine A RothblattCEOSell11,873$187.01$2,220,369.73View SEC Filing  
4/16/2015Paul A MahonEVPSell6,000$187.91$1,127,460.00View SEC Filing  
4/14/2015David ZaccardelliCOOSell3,250$185.82$603,915.00View SEC Filing  
4/14/2015Roger JeffsCEOSell10,000$185.82$1,858,200.00View SEC Filing  
4/13/2015Martine A RothblattCEOSell2,592$187.86$486,933.12View SEC Filing  
4/9/2015David ZaccardelliCOOSell4,000$184.84$739,360.00View SEC Filing  
4/9/2015Martine A RothblattCEOSell9,662$183.09$1,769,015.58View SEC Filing  
4/8/2015Martine A RothblattCEOSell2,211$181.91$402,203.01View SEC Filing  
4/7/2015David ZaccardelliCOOSell4,000$179.34$717,360.00View SEC Filing  
4/7/2015Roger JeffsCEOSell10,000$179.34$1,793,400.00View SEC Filing  
4/6/2015Martine A RothblattCEOSell2,592$176.20$456,710.40View SEC Filing  
4/2/2015David ZaccardelliCOOSell4,000$174.73$698,920.00View SEC Filing  
4/2/2015Martine A RothblattCEOSell11,873$173.43$2,059,134.39View SEC Filing  
4/2/2015Paul A MahonEVPSell6,000$174.73$1,048,380.00View SEC Filing  
4/2/2015Raymond DwekDirectorSell3,000$175.49$526,470.00View SEC Filing  
3/30/2015Martine A RothblattCEOSell2,592$177.22$459,354.24View SEC Filing  
3/26/2015David ZaccardelliCOOSell4,000$167.52$670,080.00View SEC Filing  
3/26/2015Martine A RothblattCEOSell9,662$167.03$1,613,843.86View SEC Filing  
3/25/2015Martine A RothblattCEOSell2,211$173.67$383,984.37View SEC Filing  
3/24/2015David ZaccardelliCOOSell4,500$179.51$807,795.00View SEC Filing  
3/23/2015Martine A RothblattCEOSell2,592$177.76$460,753.92View SEC Filing  
3/19/2015Paul A MahonEVPSell6,000$175.82$1,054,920.00View SEC Filing  
3/18/2015Martine A RothblattCEOSell2,211$174.64$386,129.04View SEC Filing  
3/17/2015David ZaccardelliCOOSell4,000$177.34$709,360.00View SEC Filing  
3/16/2015Martine A RothblattCEOSell2,592$170.97$443,154.24View SEC Filing  
3/12/2015Martine A RothblattCEOSell11,873$162.94$1,934,586.62View SEC Filing  
3/10/2015Roger JeffsCEOSell18,750$143.68$2,694,000.00View SEC Filing  
3/9/2015Martine A RothblattCEOSell2,592$160.51$416,041.92View SEC Filing  
3/5/2015Martine A RothblattCEOSell9,662$159.75$1,543,504.50View SEC Filing  
3/5/2015Raymond DwekDirectorSell3,000$157.59$472,770.00View SEC Filing  
3/4/2015Martine A RothblattCEOSell2,211$157.63$348,519.93View SEC Filing  
3/3/2015Roger JeffsCEOSell10,000$157.74$1,577,400.00View SEC Filing  
3/2/2015Martine A RothblattCEOSell2,592$155.32$402,589.44View SEC Filing  
2/27/2015Ray KurzweilDirectorSell15,000$155.05$2,325,750.00View SEC Filing  
2/26/2015Martine A RothblattCEOSell9,662$155.23$1,499,832.26View SEC Filing  
2/25/2015Martine A RothblattCEOSell2,211$159.35$352,322.85View SEC Filing  
2/24/2015David ZaccardelliCOOSell1,458$155.16$226,223.28View SEC Filing  
2/24/2015Roger JeffsCEOSell10,000$155.16$1,551,600.00View SEC Filing  
2/23/2015Martine A RothblattCEOSell2,592$156.08$404,559.36View SEC Filing  
2/19/2015John Maxim FerrariCFOSell10,000$155.72$1,557,200.00View SEC Filing  
2/19/2015Martine A RothblattCEOSell9,662$155.99$1,507,175.38View SEC Filing  
2/19/2015Paul A MahonEVPSell6,000$155.72$934,320.00View SEC Filing  
2/17/2015David ZaccardelliCOOSell4,000$155.14$620,560.00View SEC Filing  
2/17/2015Martine A RothblattCEOSell2,592$152.28$394,709.76View SEC Filing  
2/12/2015Martine A RothblattCEOSell9,662$146.01$1,410,748.62View SEC Filing  
2/11/2015Martine A RothblattCEOSell2,211$147.29$325,658.19View SEC Filing  
2/10/2015David ZaccardelliCOOSell4,000$146.68$586,720.00View SEC Filing  
2/10/2015Roger JeffsCEOSell10,000$146.68$1,466,800.00View SEC Filing  
2/9/2015Martine A RothblattCEOSell2,592$143.32$371,485.44View SEC Filing  
2/5/2015John Maxim FerrariCFOSell10,000$141.92$1,419,200.00View SEC Filing  
2/5/2015Martine A RothblattCEOSell11,773$141.07$1,660,817.11View SEC Filing  
2/5/2015Paul A MahonEVPSell6,000$141.92$851,520.00View SEC Filing  
2/5/2015Raymond DwekDirectorSell3,000$140.41$421,230.00View SEC Filing  
2/3/2015David ZaccardelliCOOSell4,000$141.99$567,960.00View SEC Filing  
2/3/2015Roger JeffsCEOSell10,000$141.99$1,419,900.00View SEC Filing  
1/29/2015Martine A RothblattCEOSell9,662$143.29$1,384,467.98View SEC Filing  
1/28/2015Martine A RothblattCEOSell2,211$145.49$321,678.39View SEC Filing  
1/27/2015David ZaccardelliCOOSell4,000$147.19$588,760.00View SEC Filing  
1/27/2015Roger JeffsCEOSell10,000$147.19$1,471,900.00View SEC Filing  
1/26/2015Martine A RothblattCEOSell2,592$145.89$378,146.88View SEC Filing  
1/22/2015Martine A RothblattCEOSell11,873$146.76$1,742,481.48View SEC Filing  
1/20/2015David ZaccardelliCOOSell4,000$146.48$585,920.00View SEC Filing  
1/20/2015Martine A RothblattCEOSell2,592$145.06$375,995.52View SEC Filing  
1/15/2015John Maxim FerrariCFOSell22,500$137.84$3,101,400.00View SEC Filing  
1/15/2015Martine A RothblattCEOSell9,662$137.51$1,328,621.62View SEC Filing  
1/15/2015Paul A MahonEVPSell6,000$137.84$827,040.00View SEC Filing  
1/14/2015Martine A RothblattCEOSell2,211$135.18$298,882.98View SEC Filing  
1/13/2015David ZaccardelliCOOSell3,000$134.71$404,130.00View SEC Filing  
1/13/2015Roger JeffsCEOSell10,000$134.71$1,347,100.00View SEC Filing  
1/12/2015Martine A RothblattCEOSell2,592$132.00$342,144.00View SEC Filing  
1/8/2015Christopher PatuskyDirectorSell5,000$128.13$640,650.00View SEC Filing  
1/8/2015Martine A RothblattCEOSell9,662$128.31$1,239,731.22View SEC Filing  
1/7/2015Martine A RothblattCEOSell2,211$126.04$278,674.44View SEC Filing  
1/6/2015David ZaccardelliCOOSell3,000$124.93$374,790.00View SEC Filing  
1/6/2015Roger JeffsCEOSell7,500$124.93$936,975.00View SEC Filing  
1/5/2015Martine A RothblattCEOSell2,592$126.88$328,872.96View SEC Filing  
1/2/2015Christopher CauseyDirectorSell3,000$129.25$387,750.00View SEC Filing  
1/2/2015Martine A RothblattCEOSell9,662$126.53$1,222,532.86View SEC Filing  
1/2/2015Paul A MahonEVPSell6,000$127.73$766,380.00View SEC Filing  
12/31/2014Martine A RothblattCEOSell2,211$131.35$290,414.85View SEC Filing  
12/30/2014Roger JeffsCEOSell10,000$130.80$1,308,000.00View SEC Filing  
12/29/2014Martine A RothblattCEOSell2,592$131.75$341,496.00View SEC Filing  
12/26/2014Martine A RothblattCEOSell9,662$131.85$1,273,934.70View SEC Filing  
12/24/2014Martine A RothblattCEOSell2,211$130.35$288,203.85View SEC Filing  
12/23/2014Roger JeffsCOOSell10,000$127.82$1,278,200.00View SEC Filing  
12/22/2014Martine A RothblattCEOSell2,592$133.45$345,902.40View SEC Filing  
12/19/2014Christopher CauseyDirectorSell1,500$131.47$197,205.00View SEC Filing  
12/18/2014John Maxim FerrariCFOSell10,000$131.11$1,311,100.00View SEC Filing  
12/18/2014Martine A RothblattCEOSell9,662$129.06$1,246,977.72View SEC Filing  
12/18/2014Paul A MahonEVPSell10,750$130.03$1,397,822.50View SEC Filing  
12/17/2014Martine A RothblattCEOSell2,211$126.04$278,674.44View SEC Filing  
12/15/2014Martine A RothblattCEOSell2,592$129.75$336,312.00View SEC Filing  
12/11/2014Martine A RothblattCEOSell9,662$130.98$1,265,528.76View SEC Filing  
12/10/2014Martine A RothblattCEOSell2,211$132.77$293,554.47View SEC Filing  
12/9/2014Roger JeffsCOOSell10,000$134.80$1,348,000.00View SEC Filing  
12/8/2014Martine A RothblattCEOSell2,592$132.34$343,025.28View SEC Filing  
12/4/2014John Maxim FerrariCFOSell10,000$129.05$1,290,500.00View SEC Filing  
12/4/2014Martine A RothblattCEOSell11,873$131.32$1,559,162.36View SEC Filing  
12/4/2014Paul A MahonEVPSell11,000$129.92$1,429,120.00View SEC Filing  
12/4/2014Raymond DwekDirectorSell3,000$131.58$394,740.00View SEC Filing  
12/2/2014Roger JeffsCOOSell10,000$133.63$1,336,300.00View SEC Filing  
12/1/2014Martine A RothblattCEOSell2,592$132.92$344,528.64View SEC Filing  
11/28/2014Martine A RothblattCEOSell11,873$132.77$1,576,378.21View SEC Filing  
11/25/2014Roger JeffsCOOSell10,000$131.30$1,313,000.00View SEC Filing  
11/24/2014Martine A RothblattCEOSell2,592$130.72$338,826.24View SEC Filing  
11/21/2014Roger JeffsCOOSell10,000$130.15$1,301,500.00View SEC Filing  
11/20/2014Christopher CauseyDirectorSell1,500$127.20$190,800.00View SEC Filing  
11/20/2014John Maxim FerrariCFOSell10,000$129.22$1,292,200.00View SEC Filing  
11/20/2014Martine A RothblattCEOSell9,662$128.86$1,245,045.32View SEC Filing  
11/20/2014Paul A MahonEVPSell11,000$129.02$1,419,220.00View SEC Filing  
11/19/2014Martine A RothblattCEOSell2,211$128.69$284,533.59View SEC Filing  
11/18/2014Roger JeffsCOOSell10,000$128.21$1,282,100.00View SEC Filing  
11/17/2014Martine A RothblattCEOSell2,592$125.65$325,684.80View SEC Filing  
11/13/2014Martine A RothblattCEOSell9,662$124.79$1,205,720.98View SEC Filing  
11/12/2014Martine A RothblattCEOSell2,211$122.88$271,687.68View SEC Filing  
11/10/2014Martine A RothblattCEOSell2,592$125.14$324,362.88View SEC Filing  
11/7/2014Christopher PatuskyDirectorSell5,000$124.49$622,450.00View SEC Filing  
11/7/2014Roger JeffsCOOSell10,000$124.46$1,244,600.00View SEC Filing  
11/6/2014Christopher CauseyDirectorSell1,500$122.89$184,335.00View SEC Filing  
11/6/2014Martine A RothblattCEOSell4,115$125.33$515,732.95View SEC Filing  
11/6/2014Paul A MahonEVPSell5,000$125.02$625,100.00View SEC Filing  
11/5/2014Martine A RothblattCEOSell2,211$124.31$274,849.41View SEC Filing  
11/3/2014Martine A RothblattCEOSell2,592$127.49$330,454.08View SEC Filing  
10/30/2014Martine A RothblattCEOSell9,662$130.42$1,260,118.04View SEC Filing  
10/29/2014Martine A RothblattCEOSell2,211$131.10$289,862.10View SEC Filing  
10/27/2014Martine A RothblattCEOSell2,592$132.16$342,558.72View SEC Filing  
10/23/2014Martine A RothblattCEOSell11,873$129.97$1,543,133.81View SEC Filing  
10/23/2014Paul A MahonEVPSell11,000$127.04$1,397,440.00View SEC Filing  
10/13/2014Martine A RothblattCEOSell2,592$124.31$322,211.52View SEC Filing  
10/9/2014Martine A RothblattCEOSell9,662$129.97$1,255,770.14View SEC Filing  
10/9/2014Paul A MahonEVPSell5,000$130.59$652,950.00View SEC Filing  
10/8/2014Martine A RothblattCEOSell2,211$131.50$290,746.50View SEC Filing  
10/7/2014Roger JeffsCOOSell35,000$130.14$4,554,900.00View SEC Filing  
10/6/2014Martine A RothblattCEOSell2,592$129.32$335,197.44View SEC Filing  
10/3/2014Roger JeffsCOOSell10,000$129.79$1,297,900.00View SEC Filing  
10/2/2014Christopher CauseyDirectorSell1,500$130.65$195,975.00View SEC Filing  
10/2/2014John Maxim FerrariCFOSell10,000$129.46$1,294,600.00View SEC Filing  
10/2/2014Martine A RothblattCEOSell9,662$127.72$1,234,030.64View SEC Filing  
10/2/2014Paul A MahonEVPSell6,000$129.46$776,760.00View SEC Filing  
10/1/2014Martine A RothblattCEOSell2,211$127.40$281,681.40View SEC Filing  
9/30/2014Roger JeffsCOOSell20,000$128.65$2,573,000.00View SEC Filing  
9/25/2014Martine A RothblattCEOSell5,547$134.26$744,740.22View SEC Filing  
9/25/2014Paul A MahonEVPSell5,000$133.77$668,850.00View SEC Filing  
9/25/2014Richard GiltnerDirectorSell20,000$134.94$2,698,800.00View SEC Filing  
9/23/2014Roger JeffsCOOSell50,000$131.02$6,551,000.00View SEC Filing  
9/19/2014Roger JeffsCOOSell10,000$129.60$1,296,000.00View SEC Filing  
9/18/2014John Maxim FerrariCFOSell10,000$130.93$1,309,300.00View SEC Filing  
9/18/2014Martine A RothblattCEOSell9,662$127.35$1,230,455.70View SEC Filing  
9/18/2014Paul A MahonEVPSell6,000$130.93$785,580.00View SEC Filing  
9/17/2014Roger JeffsCOOSell20,000$127.01$2,540,200.00View SEC Filing  
9/15/2014Martine A RothblattCEOSell50,000$124.52$6,226,000.00View SEC Filing  
9/11/2014Martine A RothblattCEOSell9,662$120.79$1,167,072.98View SEC Filing  
9/11/2014Paul A MahonEVPSell5,000$120.70$603,500.00View SEC Filing  
9/10/2014Martine A RothblattCEOSell50,000$120.01$6,000,500.00View SEC Filing  
9/10/2014Richard GiltnerDirectorSell20,000$119.95$2,399,000.00View SEC Filing  
9/5/2014Roger JeffsCOOSell10,000$111.29$1,112,900.00View SEC Filing  
9/4/2014John Maxim FerrariCFOSell10,000$112.38$1,123,800.00View SEC Filing  
9/4/2014Martine A RothblattCEOSell9,662$112.87$1,090,549.94View SEC Filing  
9/4/2014Paul A MahonEVPSell6,000$112.38$674,280.00View SEC Filing  
9/4/2014Raymond DwekDirectorSell3,000$113.40$340,200.00View SEC Filing  
8/28/2014Martine A RothblattCEOSell7,014$92.46$648,514.44View SEC Filing  
8/28/2014Paul A MahonEVPSell5,000$92.07$460,350.00View SEC Filing  
8/21/2014John Maxim FerrariCFOSell10,000$93.75$937,500.00View SEC Filing  
8/21/2014Martine A RothblattCEOSell9,640$93.13$897,773.20View SEC Filing  
8/15/2014Christopher CauseyDirectorSell1,500$91.14$136,710.00View SEC Filing  
8/14/2014Martine A RothblattCEOSell4,115$88.39$363,724.85View SEC Filing  
8/14/2014Paul A MahonEVPSell10,000$88.41$884,100.00View SEC Filing  
8/7/2014Christopher PatuskyDirectorSell5,000$88.23$441,150.00View SEC Filing  
8/7/2014John Maxim FerrariCFOSell10,000$86.44$864,400.00View SEC Filing  
8/7/2014Martine A RothblattCEOSell4,115$88.40$363,766.00View SEC Filing  
8/1/2014Raymond DwekDirectorSell3,000$89.52$268,560.00View SEC Filing  
8/1/2014Roger JeffsCOOSell10,000$89.88$898,800.00View SEC Filing  
7/31/2014Martine A RothblattCEOSell3,933$90.95$357,706.35View SEC Filing  
7/29/2014Roger JeffsCOOSell50,000$96.25$4,812,500.00View SEC Filing  
7/25/2014Roger JeffsCOOSell10,000$91.54$915,400.00View SEC Filing  
7/24/2014Martine A RothblattCEOSell9,228$93.15$859,588.20View SEC Filing  
7/17/2014John Maxim FerrariCFOSell10,000$89.74$897,400.00View SEC Filing  
7/17/2014Martine A RothblattCEOSell3,833$90.87$348,304.71View SEC Filing  
7/11/2014Roger JeffsCOOSell10,000$93.06$930,600.00View SEC Filing  
7/10/2014Martine A RothblattCEOSell9,187$92.33$848,235.71View SEC Filing  
7/3/2014Christopher CauseyDirectorSell1,500$91.62$137,430.00View SEC Filing  
7/3/2014John Maxim FerrariCFOSell10,000$90.58$905,800.00View SEC Filing  
7/3/2014Martine A RothblattCEOSell3,833$91.37$350,221.21View SEC Filing  
6/26/2014Martine A RothblattCEOSell3,833$87.23$334,352.59View SEC Filing  
6/20/2014Roger JeffsCOOSell10,000$87.00$870,000.00View SEC Filing  
6/19/2014John Maxim FerrariCFOSell10,000$87.02$870,200.00View SEC Filing  
6/19/2014Martine A RothblattCEOSell3,833$85.68$328,411.44View SEC Filing  
6/19/2014Paul A MahonEVPSell2,000$85.67$171,340.00View SEC Filing  
6/12/2014Martine A RothblattCEOSell9,066$98.22$890,462.52View SEC Filing  
6/10/2014Roger JeffsCOOSell10,000$96.29$962,900.00View SEC Filing  
6/9/2014Roger JeffsCOOSell10,000$96.32$963,200.00View SEC Filing  
6/5/2014Christopher CauseyDirectorSell1,500$96.48$144,720.00View SEC Filing  
6/5/2014Martine A RothblattCEOSell9,066$96.46$874,506.36View SEC Filing  
6/5/2014Paul A MahonEVPSell6,000$96.50$579,000.00View SEC Filing  
6/3/2014Roger JeffsCOOSell10,000$95.00$950,000.00View SEC Filing  
5/29/2014Martine A RothblattCEOSell9,066$95.27$863,717.82View SEC Filing  
5/27/2014Roger JeffsCOOSell10,000$99.14$991,400.00View SEC Filing  
5/22/2014Louis SullivanDirectorSell30,000$101.46$3,043,800.00View SEC Filing  
5/22/2014Martine RothblattCEOSell9,066$101.35$918,839.10View SEC Filing  
5/20/2014Roger JeffsCOOSell10,000$99.91$999,100.00View SEC Filing  
5/16/2014Roger JeffsCOOSell10,000$100.00$1,000,000.00View SEC Filing  
5/15/2014John Maxim FerrariCFOSell10,000$101.49$1,014,900.00View SEC Filing  
5/15/2014Martine RothblattCEOSell9,066$100.88$914,578.08View SEC Filing  
5/15/2014Paul MahonEVPSell6,000$100.86$605,160.00View SEC Filing  
5/13/2014Roger JeffsCOOSell10,000$105.53$1,055,300.00View SEC Filing  
5/8/2014Christopher PatuskyDirectorSell5,000$107.17$535,850.00View SEC Filing  
5/8/2014Martine RothblattCEOSell9,066$107.83$977,586.78View SEC Filing  
5/6/2014Roger JeffsCOOSell10,000$106.50$1,065,000.00View SEC Filing  
5/2/2014Roger JeffsCOOSell10,000$102.00$1,020,000.00View SEC Filing  
5/1/2014Christopher CauseyDirectorSell1,500$99.30$148,950.00View SEC Filing  
5/1/2014John Maxim FerrariCFOSell10,000$102.20$1,022,000.00View SEC Filing  
5/1/2014Martine RothblattCEOSell9,066$101.84$923,281.44View SEC Filing  
5/1/2014Paul MahonEVPSell6,000$102.71$616,260.00View SEC Filing  
4/29/2014Roger JeffsCOOSell10,000$95.00$950,000.00View SEC Filing  
4/24/2014Martine RothblattCEOSell9,066$92.45$838,151.70View SEC Filing  
4/22/2014Roger JeffsCOOSell10,000$96.00$960,000.00View SEC Filing  
4/17/2014John Maxim FerrariCFOSell10,000$96.20$962,000.00View SEC Filing  
4/17/2014Martine RothblattCEOSell9,066$98.48$892,819.68View SEC Filing  
4/17/2014Paul MahonEVPSell6,000$98.37$590,220.00View SEC Filing  
4/15/2014Roger JeffsCOOSell10,000$95.06$950,600.00View SEC Filing  
4/10/2014Martine RothblattCEOSell9,066$96.18$871,967.88View SEC Filing  
4/8/2014Roger JeffsCOOSell10,000$95.00$950,000.00View SEC Filing  
4/4/2014Roger JeffsCOOSell10,000$93.22$932,200.00View SEC Filing  
4/3/2014Christopher CauseyDirectorSell1,500$95.67$143,505.00View SEC Filing  
4/3/2014John Maxim FerrariCFOSell10,000$93.22$932,200.00View SEC Filing  
4/3/2014Martine RothblattCEOSell9,066$93.74$849,846.84View SEC Filing  
4/3/2014Paul MahonEVPSell6,000$93.10$558,600.00View SEC Filing  
4/1/2014Roger JeffsCOOSell10,000$95.44$954,400.00View SEC Filing  
3/27/2014Martine RothblattCEOSell9,066$93.35$846,311.10View SEC Filing  
3/25/2014Roger JeffsCOOSell10,000$95.64$956,400.00View SEC Filing  
3/21/2014Roger JeffsCOOSell10,000$93.84$938,400.00View SEC Filing  
3/20/2014Christopher CauseyDirectorSell1,500$96.04$144,060.00View SEC Filing  
3/20/2014John Maxim FerrariCFOSell10,000$96.11$961,100.00View SEC Filing  
3/20/2014Martine RothblattCEOSell9,065$96.76$877,129.40View SEC Filing  
3/20/2014Paul MahonEVPSell6,000$96.81$580,860.00View SEC Filing  
3/18/2014Roger JeffsCOOSell10,000$96.51$965,100.00View SEC Filing  
3/13/2014Martine RothblattCEOSell3,833$95.64$366,588.12View SEC Filing  
3/7/2014Roger JeffsCOOSell10,000$99.02$990,200.00View SEC Filing  
3/6/2014Christopher PatuskyDirectorSell5,000$101.39$506,950.00View SEC Filing  
3/6/2014John Maxim FerrariCFOSell10,000$99.07$990,700.00View SEC Filing  
3/6/2014Martine RothblattCEOSell3,833$102.77$393,917.41View SEC Filing  
3/6/2014Paul MahonEVPSell6,000$101.93$611,580.00View SEC Filing  
2/28/2014Ray KurzweilDirectorSell15,000$101.42$1,521,300.00View SEC Filing  
2/27/2014Martine RothblattCEOSell3,833$100.68$385,906.44View SEC Filing  
2/21/2014Roger JeffsCOOSell10,000$104.89$1,048,900.00View SEC Filing  
2/20/2014Martine RothblattCEOSell3,833$103.91$398,287.03View SEC Filing  
2/20/2014Paul MahonEVPSell6,000$104.63$627,780.00View SEC Filing  
2/13/2014Martine RothblattCEOSell3,833$99.87$382,801.71View SEC Filing  
2/7/2014Roger JeffsCOOSell10,000$96.61$966,100.00View SEC Filing  
2/6/2014Martine RothblattCEOSell3,833$97.26$372,797.58View SEC Filing  
2/6/2014Paul MahonEVPSell6,000$97.41$584,460.00View SEC Filing  
2/6/2014Raymond DwekDirectorSell3,000$97.33$291,990.00View SEC Filing  
1/30/2014Martine RothblattCEOSell3,833$106.25$407,256.25View SEC Filing  
1/23/2014Martine RothblattCEOSell3,833$111.78$428,452.74View SEC Filing  
1/17/2014Roger JeffsCOOSell10,000$113.03$1,130,300.00View SEC Filing  
1/16/2014Martine RothblattCEOSell3,833$111.21$426,267.93View SEC Filing  
1/16/2014Paul MahonEVPSell6,000$111.98$671,880.00View SEC Filing  
1/9/2014Christopher PatuskyDirectorSell5,000$110.00$550,000.00View SEC Filing  
1/9/2014Martine RothblattCEOSell3,833$108.35$415,305.55View SEC Filing  
1/3/2014Roger JeffsCOOSell10,000$110.72$1,107,200.00View SEC Filing  
1/2/2014Martine RothblattCEOSell3,833$111.54$427,532.82View SEC Filing  
1/2/2014Paul MahonEVPSell6,000$110.78$664,680.00View SEC Filing  
1/2/2014Raymond DwekDirectorSell3,000$111.41$334,230.00View SEC Filing  
12/31/2013Martine RothblattCEOSell18,140$112.64$2,043,289.60View SEC Filing  
12/30/2013Martine RothblattCEOSell18,147$111.60$2,025,205.20View SEC Filing  
12/27/2013Martine RothblattCEOSell18,147$113.15$2,053,333.05View SEC Filing  
12/26/2013Martine RothblattCEOSell21,981$111.95$2,460,772.95View SEC Filing  
12/24/2013Martine RothblattCEOSell18,149$114.05$2,069,893.45View SEC Filing  
12/23/2013Martine RothblattCEOSell5,743$109.71$630,064.53View SEC Filing  
12/20/2013Martine RothblattCEOSell18,149$86.72$1,573,881.28View SEC Filing  
12/20/2013Roger JeffsCOOSell8,250$87.84$724,680.00View SEC Filing  
12/19/2013Martine RothblattCEOSell21,982$86.73$1,906,498.86View SEC Filing  
12/19/2013Paul MahonEVPSell6,000$86.45$518,700.00View SEC Filing  
12/18/2013Martine RothblattCEOSell18,149$86.36$1,567,347.64View SEC Filing  
12/17/2013Martine RothblattCEOSell12,251$86.49$1,059,588.99View SEC Filing  
12/6/2013Roger JeffsCOOSell10,000$90.97$909,700.00View SEC Filing  
12/5/2013Martine RothblattCEOSell3,833$89.79$344,165.07View SEC Filing  
12/5/2013Paul MahonEVPSell6,000$89.18$535,080.00View SEC Filing  
12/5/2013Raymond DwekDirectorSell3,000$90.13$270,390.00View SEC Filing  
11/21/2013Martine RothblattCEOSell3,833$92.49$354,514.17View SEC Filing  
11/21/2013Paul MahonEVPSell6,000$92.47$554,820.00View SEC Filing  
11/15/2013Roger JeffsCOOSell10,000$94.00$940,000.00View SEC Filing  
11/14/2013Christopher PatuskyDirectorSell5,500$91.65$504,075.00View SEC Filing  
11/14/2013Martine RothblattCEOSell3,833$91.60$351,102.80View SEC Filing  
11/7/2013Christopher PatuskyDirectorSell3,500$90.51$316,785.00View SEC Filing  
11/7/2013Martine RothblattCEOSell3,833$89.47$342,938.51View SEC Filing  
11/7/2013Paul MahonEVPSell6,000$89.60$537,600.00View SEC Filing  
11/1/2013Raymond DwekDirectorSell3,000$89.18$267,540.00View SEC Filing  
11/1/2013Roger JeffsCOOSell10,000$90.34$903,400.00View SEC Filing  
10/31/2013Martine A RothblattCEOSell3,833$86.89$333,049.37View SEC Filing  
10/24/2013Martine A RothblattCEOSell3,833$83.77$321,090.41View SEC Filing  
10/18/2013Roger JeffsCOOSell10,000$82.47$824,700.00View SEC Filing  
10/17/2013John Maxim FerrariCFOSell2,750$82.01$225,527.50View SEC Filing  
10/17/2013Martine A RothblattCEOSell3,833$81.84$313,692.72View SEC Filing  
10/17/2013Paul A MahonEVPSell6,000$81.79$490,740.00View SEC Filing  
10/10/2013Martine RothblattCEOSell3,833$82.58$316,529.14View SEC Filing  
10/4/2013Roger JeffsCOOSell10,000$85.48$854,800.00View SEC Filing  
10/3/2013Christopher CauseyDirectorSell1,500$83.15$124,725.00View SEC Filing  
10/3/2013John Maxim FerrariCFOSell4,500$84.67$381,015.00View SEC Filing  
10/3/2013Martine A RothblattCEOSell3,833$84.20$322,738.60View SEC Filing  
10/3/2013Paul A MahonEVPSell6,000$84.38$506,280.00View SEC Filing  
9/26/2013Martine RothblattCEOSell3,833$78.41$300,545.53View SEC Filing  
9/20/2013Roger JeffsCOOSell10,000$77.86$778,600.00View SEC Filing  
9/19/2013John Maxim FerrariCFOSell4,500$78.67$354,015.00View SEC Filing  
9/19/2013Martine RothblattCEOSell3,833$78.12$299,433.96View SEC Filing  
9/19/2013Paul MahonEVPSell6,000$78.02$468,120.00View SEC Filing  
9/12/2013Martine A RothblattCEOSell3,833$76.98$295,064.34View SEC Filing  
9/6/2013Roger JeffsCOOSell10,000$73.67$736,700.00View SEC Filing  
9/5/2013Christopher CauseyDirectorSell1,500$73.11$109,665.00View SEC Filing  
9/5/2013John Maxim FerrariCFOSell4,500$74.17$333,765.00View SEC Filing  
9/5/2013Martine A RothblattCEOSell3,833$73.63$282,223.79View SEC Filing  
9/5/2013Paul A MahonEVPSell6,000$73.29$439,740.00View SEC Filing  
8/29/2013Martine RothblattCEOSell3,833$72.76$278,889.08View SEC Filing  
8/22/2013Martine RothblattCEOSell3,833$72.06$276,205.98View SEC Filing  
8/16/2013Roger JeffsCOOSell10,000$71.21$712,100.00View SEC Filing  
8/15/2013John Maxim FerrariCFOSell4,500$71.14$320,130.00View SEC Filing  
8/15/2013Martine RothblattCEOSell3,833$71.58$274,366.14View SEC Filing  
8/15/2013Paul MahonEVPSell6,000$71.34$428,040.00View SEC Filing  
8/8/2013Martine RothblattCEOSell3,833$73.11$280,230.63View SEC Filing  
8/2/2013Roger JeffsCOOSell10,000$76.69$766,900.00View SEC Filing  
8/1/2013John Maxim FerrariCFOSell4,500$75.87$341,415.00View SEC Filing  
8/1/2013Martine A RothblattCEOSell3,833$75.97$291,193.01View SEC Filing  
8/1/2013Paul A MahonEVPSell6,000$75.91$455,460.00View SEC Filing  
8/1/2013Raymond DwekDirectorSell3,000$75.94$227,820.00View SEC Filing  
7/31/2013R Paul GrayDirectorSell7,500$74.93$561,975.00View SEC Filing  
7/25/2013Martine A RothblattCEOSell3,833$71.45$273,867.85View SEC Filing  
7/19/2013Roger JeffsCOOSell10,000$70.00$700,000.00View SEC Filing  
7/18/2013John Maxim FerrariCFOSell9,000$69.85$628,650.00View SEC Filing  
7/18/2013Martine A RothblattCEOSell3,833$68.96$264,323.68View SEC Filing  
7/18/2013Paul A MahonEVPSell6,000$69.15$414,900.00View SEC Filing  
7/11/2013Martine A RothblattCEOSell3,837$67.94$260,685.78View SEC Filing  
7/5/2013Christopher CauseyDirectorSell1,500$66.33$99,495.00View SEC Filing  
7/5/2013Martine A RothblattCEOSell3,863$67.28$259,902.64View SEC Filing  
7/5/2013Paul A MahonEVPSell6,000$67.04$402,240.00View SEC Filing  
7/5/2013Roger JeffsCOOSell10,000$67.21$672,100.00View SEC Filing  
6/21/2013Roger JeffsCOOSell10,000$63.34$633,400.00View SEC Filing  
6/20/2013John Maxim FerrariCFOSell4,500$63.22$284,490.00View SEC Filing  
6/20/2013Paul A MahonEVPSell6,000$63.29$379,740.00View SEC Filing  
6/7/2013Roger JeffsCOOSell10,000$67.00$670,000.00View SEC Filing  
6/6/2013John Maxim FerrariCFOSell4,500$64.84$291,780.00View SEC Filing  
6/6/2013Paul A MahonEVPSell6,000$63.84$383,040.00View SEC Filing  
6/6/2013Raymond DwekDirectorSell3,000$63.77$191,310.00View SEC Filing  
5/17/2013Roger JeffsCOOSell10,000$69.17$691,700.00View SEC Filing  
5/16/2013John Maxim FerrariCFOSell4,500$68.48$308,160.00View SEC Filing  
5/16/2013Paul A MahonEVPSell6,000$68.05$408,300.00View SEC Filing  
5/2/2013Paul A MahonEVPSell6,000$67.15$402,900.00View SEC Filing  
5/2/2013Raymond DwekDirectorSell3,000$66.75$200,250.00View SEC Filing  
4/11/2013Raymond DwekDirectorSell9,000$61.35$552,150.00View SEC Filing  
1/17/2013Paul A MahonEVPSell5,749$52.20$300,097.80View SEC Filing  
12/28/2012Martine A RothblattCEOBuy4,167$52.40$218,350.80View SEC Filing  
12/26/2012Martine A RothblattCEOBuy6,000$52.40$314,400.00View SEC Filing  
12/21/2012Martine A RothblattCEOBuy9,000$51.85$466,650.00View SEC Filing  
11/26/2012Christopher CauseyDirectorSell1,500$53.33$79,995.00View SEC Filing  
10/4/2012Christopher CauseyDirectorSell1,500$58.33$87,495.00View SEC Filing  
10/4/2012John Maxim FerrariCFOSell1,550$58.00$89,900.00View SEC Filing  
10/4/2012Paul A MahonEVPSell6,000$38.00$228,000.00View SEC Filing  
9/6/2012Christopher CauseyDirectorSell1,500$55.94$83,910.00View SEC Filing  
9/5/2012Christopher PatuskyDirectorSell2,000$55.47$110,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for United Therapeutics (NASDAQ:UTHR)
Latest Headlines for United Therapeutics (NASDAQ:UTHR)
Source:
DateHeadline
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) CEO Sells $152,227.92 in Stock
www.americanbankingnews.com - May 22 at 10:22 AM
americanbankingnews.com logoFY2021 EPS Estimates for United Therapeutics Co. Reduced by Analyst (UTHR)
www.americanbankingnews.com - May 17 at 2:52 PM
finance.yahoo.com logoBlog Coverage: Ionis Pharma Reported Positive Phase III Results in Patients with Familial Amyloid Polyneuropathy
finance.yahoo.com - May 16 at 8:26 AM
finance.yahoo.com logoETFs with exposure to United Therapeutics Corp. : May 15, 2017
finance.yahoo.com - May 15 at 7:37 PM
americanbankingnews.com logoInsider Selling: United Therapeutics Co. (UTHR) CEO Sells 1,259 Shares of Stock
www.americanbankingnews.com - May 15 at 11:40 AM
americanbankingnews.com logoShort Interest in United Therapeutics Co. (UTHR) Decreases By 0.1%
www.americanbankingnews.com - May 13 at 7:10 AM
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 12 at 6:42 PM
americanbankingnews.com logoMartine A. Rothblatt Sells 1,258 Shares of United Therapeutics Co. (UTHR) Stock
www.americanbankingnews.com - May 5 at 8:37 PM
americanbankingnews.com logoUnited Therapeutics (UTHR) Earns Media Sentiment Score of 0.22
www.americanbankingnews.com - May 3 at 8:12 PM
finance.yahoo.com logoETFs with exposure to United Therapeutics Corp. : May 2, 2017
finance.yahoo.com - May 2 at 6:33 PM
finance.yahoo.com logoUnited Therapeutics Corp. :UTHR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017
finance.yahoo.com - May 1 at 7:35 PM
americanbankingnews.com logoQ3 2017 Earnings Forecast for United Therapeutics Co. Issued By Leerink Swann (UTHR)
www.americanbankingnews.com - May 1 at 8:42 AM
americanbankingnews.com logoUnited Therapeutics Co. to Post Q2 2017 Earnings of $3.80 Per Share, Jefferies Group Forecasts (UTHR)
www.americanbankingnews.com - May 1 at 7:15 AM
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) Expected to Post Q2 2017 Earnings of $3.53 Per Share
www.americanbankingnews.com - May 1 at 7:14 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Very Likely to Affect United Therapeutics (UTHR) Stock Price
www.americanbankingnews.com - April 30 at 9:06 AM
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) Expected to Announce Quarterly Sales of $420.88 Million
www.americanbankingnews.com - April 29 at 9:52 AM
americanbankingnews.com logoMartine A. Rothblatt Sells 1,262 Shares of United Therapeutics Co. (UTHR) Stock
www.americanbankingnews.com - April 29 at 1:19 AM
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 29 at 1:05 AM
streetinsider.com logoUnited Therapeutics (UTHR) Announces $250M Buyback Program
www.streetinsider.com - April 29 at 12:38 AM
seekingalpha.com logoUnited Therapeutics to buy back $250M in shares
seekingalpha.com - April 29 at 12:38 AM
finance.yahoo.com logoUnited Therapeutics Announces $250 Million Share Repurchase Program
finance.yahoo.com - April 29 at 12:38 AM
finance.yahoo.com logoUnited Therapeutics' Martine Rothblatt saw pay jump last year in midst of executive shakeup
finance.yahoo.com - April 29 at 12:38 AM
americanbankingnews.com logoBrokers Offer Predictions for United Therapeutics Co.'s FY2018 Earnings (UTHR)
www.americanbankingnews.com - April 28 at 11:28 PM
americanbankingnews.com logoUnited Therapeutics Co. Forecasted to Earn Q3 2017 Earnings of $3.77 Per Share (UTHR)
www.americanbankingnews.com - April 28 at 12:52 PM
americanbankingnews.com logoUnited Therapeutics Co. to Post Q2 2017 Earnings of $3.43 Per Share, Leerink Swann Forecasts (UTHR)
www.americanbankingnews.com - April 28 at 8:24 AM
bizjournals.com logoUnited Therapeutics partners with 3-D printer to make human organs - Washington Business Journal
www.bizjournals.com - April 27 at 10:45 PM
americanbankingnews.com logoSomewhat Positive News Coverage Likely to Affect United Therapeutics (UTHR) Share Price
www.americanbankingnews.com - April 27 at 12:36 PM
zacks.com logoUnited Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
www.zacks.com - April 27 at 11:44 AM
seekingalpha.com logoUnited Therapeutics (UTHR) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 27 at 11:44 AM
finance.yahoo.com logoEdited Transcript of UTHR earnings conference call or presentation 26-Apr-17 1:00pm GMT
finance.yahoo.com - April 27 at 11:44 AM
finance.yahoo.com logoBlog Coverage3D Systems and United Therapeutics Partner to Develop 3D Bioprinted Lungs
finance.yahoo.com - April 27 at 11:44 AM
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) PT Lowered to $213.00
www.americanbankingnews.com - April 27 at 9:26 AM
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) Expected to Announce Earnings of $3.62 Per Share
www.americanbankingnews.com - April 27 at 9:08 AM
americanbankingnews.com logoUnited Therapeutics' (UTHR) "Hold" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - April 26 at 10:14 PM
finance.yahoo.com logo3D Systems signs 'bioprinting' agreement to eventually create human organs
finance.yahoo.com - April 26 at 5:00 PM
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) Releases Earnings Results, Beats Estimates By $0.77 EPS
www.americanbankingnews.com - April 26 at 3:27 PM
finance.yahoo.com logo3D Systems and United Therapeutics Announce Bioprinting Agreement
finance.yahoo.com - April 26 at 8:28 AM
finance.yahoo.com logoUnited Therapeutics Corporation Reports First Quarter 2017 Financial Results
finance.yahoo.com - April 26 at 8:28 AM
finance.yahoo.com logoUnited Therapeutics beats 1Q profit forecasts
finance.yahoo.com - April 26 at 8:28 AM
bizjournals.com logoResearch Reports Initiation on Drug Makers Stocks -- Depomed, Pernix Therapeutics, Orexigen Therapeutics, and United Therapeutics
www.bizjournals.com - April 25 at 8:57 AM
americanbankingnews.com logoSomewhat Negative Press Coverage Likely to Impact United Therapeutics (UTHR) Stock Price
www.americanbankingnews.com - April 24 at 12:38 PM
americanbankingnews.com logoUnited Therapeutics (UTHR) Receiving Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 21 at 9:36 PM
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) CEO Sells $152,636.40 in Stock
www.americanbankingnews.com - April 21 at 9:04 PM
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) to Post FY2019 Earnings of $7.49 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 21 at 5:32 PM
finance.yahoo.com logoUnited Therapeutics Corporation To Report First Quarter 2017 Financial Results Before The Market Opens On ... - Yahoo Finance
finance.yahoo.com - April 19 at 8:28 AM
finance.yahoo.com logoUnited Therapeutics Corporation To Report First Quarter 2017 Financial Results Before The Market Opens On Wednesday, April 26, 2017
finance.yahoo.com - April 19 at 8:28 AM
americanbankingnews.com logoUnited Therapeutics (UTHR) Receives Daily Coverage Optimism Score of 0.12
www.americanbankingnews.com - April 18 at 2:32 PM
americanbankingnews.com logoHC Wainwright Reaffirms "Hold" Rating for United Therapeutics Co. (UTHR)
www.americanbankingnews.com - April 17 at 5:20 PM
americanbankingnews.com logoUnited Therapeutics Co. (UTHR) Given a $125.00 Price Target by JPMorgan Chase & Co. Analysts
www.americanbankingnews.com - April 14 at 3:34 PM
americanbankingnews.com logoUnited Therapeutics (UTHR) Earns News Sentiment Rating of 0.15
www.americanbankingnews.com - April 14 at 2:12 PM

Social

United Therapeutics (UTHR) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff